losartan has been researched along with Hyperplasia in 20 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Hyperplasia: An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of the present study was to test whether calcineurin is involved in the signal transduction of angiotensin II (AngII)-induced cardiac myocyte hypertrophy and fibroblast hyperplasia." | 7.70 | Involvement of calcineurin in angiotensin II-induced cardiomyocyte hypertrophy and cardiac fibroblast hyperplasia of rats. ( Fu, M; Liu, N; Pang, Y; Su, J; Tang, C; Xu, S; Zhang, J, 1999) |
| "Juxtaglomerular (JG) cell hypertrophy and hyperplasia were investigated in rhesus monkeys given angiotensin II (AII) AT1 receptor antagonists L-158,338 and DUP 753 (MK-0954, losartan)." | 7.69 | Juxtaglomerular cell hypertrophy and hyperplasia induced in rhesus monkeys by angiotensin II receptor antagonists. ( Eydelloth, RS; Hubert, MF; Keenan, KP; Molon-Noblot, S; Owen, RA; Siegl, PK, 1994) |
| "Treatment with losartan may be a viable approach for controlling neointimal hyperplasia at locations (eg, grafts) that are accessible during a surgical procedure." | 5.32 | Perivascular delivery of losartan with surgical fibrin glue prevents neointimal hyperplasia after arterial injury. ( Molnar, K; Moon, MC; Yau, L; Zahradka, P, 2004) |
| "Intimal hyperplasia is a serious problem after percutaneous transluminal coronary angioplasty (PTCA)." | 5.29 | Tranilast suppresses intimal hyperplasia in the balloon injury model and cuff treatment model in rabbits. ( Fukuyama, J; Hamano, S; Ichikawa, K; Miyazawa, K; Shibata, N; Ujiie, A, 1996) |
| "Losartan treatment improved PVS-associated pulmonary hypertension and intimal hyperplasia and might be a beneficial prophylactic therapy for patients at high risk of developing PVS after pulmonary vein surgery." | 3.80 | Losartan ameliorates "upstream" pulmonary vein vasculopathy in a piglet model of pulmonary vein stenosis. ( Caldarone, CA; Coles, JG; Fu, YY; Ide, H; Kato, H; Maynes, JT; Teichert, AM; Weisel, RD; Zhu, J, 2014) |
| " The aim of the present study was to test whether calcineurin is involved in the signal transduction of angiotensin II (AngII)-induced cardiac myocyte hypertrophy and fibroblast hyperplasia." | 3.70 | Involvement of calcineurin in angiotensin II-induced cardiomyocyte hypertrophy and cardiac fibroblast hyperplasia of rats. ( Fu, M; Liu, N; Pang, Y; Su, J; Tang, C; Xu, S; Zhang, J, 1999) |
| "Juxtaglomerular (JG) cell hypertrophy and hyperplasia were investigated in rhesus monkeys given angiotensin II (AII) AT1 receptor antagonists L-158,338 and DUP 753 (MK-0954, losartan)." | 3.69 | Juxtaglomerular cell hypertrophy and hyperplasia induced in rhesus monkeys by angiotensin II receptor antagonists. ( Eydelloth, RS; Hubert, MF; Keenan, KP; Molon-Noblot, S; Owen, RA; Siegl, PK, 1994) |
| "An organ culture of human saphenous vein was used as a model of vein graft intimal hyperplasia and the potential of Losartan, an angiotensin II receptor antagonist, to inhibit neointimal proliferation was investigated." | 3.69 | Influence of Losartan, an angiotensin receptor antagonist, on neointimal proliferation in cultured human saphenous vein. ( Allen, KE; Bell, PR; Jones, L; London, NJ; Sayers, RD; Varty, K, 1994) |
| "Treatment with losartan may be a viable approach for controlling neointimal hyperplasia at locations (eg, grafts) that are accessible during a surgical procedure." | 1.32 | Perivascular delivery of losartan with surgical fibrin glue prevents neointimal hyperplasia after arterial injury. ( Molnar, K; Moon, MC; Yau, L; Zahradka, P, 2004) |
| "Losartan or placebo treatment was initiated two days before balloon injury in the SHR aorta." | 1.31 | Losartan-induced apoptosis as a novel mechanism for the prevention of vascular lesion formation after injury. ( deBlois, D; Hamet, P; Lemay, J, 2000) |
| "Treatment with losartan, an angiotensin II AT(1) receptor antagonist, decreased BP in two-renin gene mice but not in one-renin gene mice." | 1.31 | Blood pressure, cardiac, and renal responses to salt and deoxycorticosterone acetate in mice: role of Renin genes. ( Brunner, HR; Burnier, M; Clément, S; Gabbiani, G; Hummler, E; Nussberger, J; Wang, Q, 2002) |
| "Losartan was used to assess the influence of the AT(1) receptor on SMC proliferation." | 1.30 | Focal expression of angiotensin II type 1 receptor and smooth muscle cell proliferation in the neointima of experimental vein grafts: relation to eddy blood flow. ( Liu, SQ, 1999) |
| "Intimal hyperplasia is a serious problem after percutaneous transluminal coronary angioplasty (PTCA)." | 1.29 | Tranilast suppresses intimal hyperplasia in the balloon injury model and cuff treatment model in rabbits. ( Fukuyama, J; Hamano, S; Ichikawa, K; Miyazawa, K; Shibata, N; Ujiie, A, 1996) |
| "CGP 42112A was as effective in preventing neointima formation as perindopril (-73%, p < 0." | 1.28 | Role of angiotensin subtype 2 receptor in neointima formation after vascular injury. ( Janiak, P; Pillon, A; Prost, JF; Vilaine, JP, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (45.00) | 18.2507 |
| 2000's | 5 (25.00) | 29.6817 |
| 2010's | 6 (30.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhu, J | 1 |
| Ide, H | 1 |
| Fu, YY | 1 |
| Teichert, AM | 1 |
| Kato, H | 1 |
| Weisel, RD | 1 |
| Maynes, JT | 1 |
| Coles, JG | 1 |
| Caldarone, CA | 1 |
| Afroze, SH | 1 |
| Munshi, MK | 1 |
| Martínez, AK | 1 |
| Uddin, M | 1 |
| Gergely, M | 1 |
| Szynkarski, C | 1 |
| Guerrier, M | 1 |
| Nizamutdinov, D | 1 |
| Dostal, D | 1 |
| Glaser, S | 1 |
| Owens, AP | 1 |
| Subramanian, V | 1 |
| Moorleghen, JJ | 1 |
| Guo, Z | 1 |
| McNamara, CA | 1 |
| Cassis, LA | 1 |
| Daugherty, A | 1 |
| Yi, I | 1 |
| Lee, JJ | 1 |
| Park, JS | 1 |
| Zhang, WY | 1 |
| Kim, IS | 1 |
| Kim, Y | 1 |
| Shin, CY | 1 |
| Kim, HS | 1 |
| Myung, CS | 1 |
| Valente, AJ | 1 |
| Yoshida, T | 1 |
| Murthy, SN | 1 |
| Sakamuri, SS | 1 |
| Katsuyama, M | 1 |
| Clark, RA | 1 |
| Delafontaine, P | 1 |
| Chandrasekar, B | 1 |
| Lawnicka, H | 1 |
| Ptasinska-Wnuk, D | 1 |
| Mucha, S | 2 |
| Kunert-Radek, J | 2 |
| Pawlikowski, M | 2 |
| Stepien, H | 1 |
| Moon, MC | 1 |
| Molnar, K | 1 |
| Yau, L | 1 |
| Zahradka, P | 1 |
| Ge, J | 1 |
| Huang, D | 1 |
| Liang, C | 1 |
| Luo, Y | 1 |
| Jia, Q | 1 |
| Wang, K | 1 |
| Baumann, M | 1 |
| Bartholome, R | 1 |
| Peutz-Kootstra, CJ | 1 |
| Smits, JF | 1 |
| Struijker-Boudier, HA | 1 |
| Sepien, H | 1 |
| Pisarek, H | 1 |
| Stawowy, A | 1 |
| Owen, RA | 1 |
| Molon-Noblot, S | 1 |
| Hubert, MF | 1 |
| Siegl, PK | 1 |
| Eydelloth, RS | 1 |
| Keenan, KP | 1 |
| Varty, K | 1 |
| Allen, KE | 1 |
| Jones, L | 1 |
| Sayers, RD | 1 |
| Bell, PR | 1 |
| London, NJ | 1 |
| Fukuyama, J | 1 |
| Ichikawa, K | 1 |
| Miyazawa, K | 1 |
| Hamano, S | 1 |
| Shibata, N | 1 |
| Ujiie, A | 1 |
| Peiró, C | 1 |
| Angulo, J | 1 |
| Regadera, J | 1 |
| Llergo, JL | 1 |
| Sánchez-Ferrer, A | 1 |
| Rodríguez-Mañas, L | 1 |
| Sánchez-Ferrer, CF | 1 |
| Liu, SQ | 1 |
| Kim, DK | 1 |
| Huh, JE | 1 |
| Lee, SH | 1 |
| Hong, KP | 1 |
| Park, JE | 1 |
| Seo, JD | 1 |
| Lee, WR | 1 |
| Fu, M | 1 |
| Xu, S | 1 |
| Zhang, J | 1 |
| Pang, Y | 1 |
| Liu, N | 1 |
| Su, J | 1 |
| Tang, C | 1 |
| Lemay, J | 1 |
| Hamet, P | 1 |
| deBlois, D | 1 |
| Wang, Q | 1 |
| Hummler, E | 1 |
| Nussberger, J | 1 |
| Clément, S | 1 |
| Gabbiani, G | 1 |
| Brunner, HR | 1 |
| Burnier, M | 1 |
| Janiak, P | 1 |
| Pillon, A | 1 |
| Prost, JF | 1 |
| Vilaine, JP | 1 |
20 other studies available for losartan and Hyperplasia
| Article | Year |
|---|---|
Losartan ameliorates "upstream" pulmonary vein vasculopathy in a piglet model of pulmonary vein stenosis.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Antigens, CD; Cadherins; Constri | 2014 |
Activation of the renin-angiotensin system stimulates biliary hyperplasia during cholestasis induced by extrahepatic bile duct ligation.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Bile Ducts, Extrahepatic; Cell Lin | 2015 |
Angiotensin II induces a region-specific hyperplasia of the ascending aorta through regulation of inhibitor of differentiation 3.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Blood Pressure; Hyperplasia | 2010 |
Enhanced effect of losartan and rosuvastatin on neointima hyperplasia.
Topics: Animals; DNA; Dose-Response Relationship, Drug; Drug Synergism; Femoral Artery; Fluorobenzenes; Hydr | 2010 |
Angiotensin II enhances AT1-Nox1 binding and stimulates arterial smooth muscle cell migration and proliferation through AT1, Nox1, and interleukin-18.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Carotid Arteries; Cell Movement; C | 2012 |
The involvement of angiotensin type 1 and type 2 receptors in estrogen-induced cell proliferation and vascular endothelial growth factor expression in the rat anterior pituitary.
Topics: Animals; Captopril; Cell Proliferation; Diethylstilbestrol; Estrogens; Gene Expression Regulation; H | 2012 |
Perivascular delivery of losartan with surgical fibrin glue prevents neointimal hyperplasia after arterial injury.
Topics: Administration, Topical; Angioplasty, Balloon; Angiotensin Receptor Antagonists; Animals; Antihypert | 2004 |
Upregulation of lectinlike oxidized low-density lipoprotein receptor-1 expression contributes to the vein graft atherosclerosis: modulation by losartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Arteries; Arteriosclerosis; Blotting, Western; End | 2004 |
Sustained tubulo-interstitial protection in SHRs by transient losartan treatment: an effect of decelerated aging?
Topics: Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Cell Cycle; Cell Division; Hyperplasia; Hyp | 2008 |
Is estrogen-induced pituitary hyperplasia and hyperprolactinaemia mediated by angiotensin II?
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Biphenyl | 1995 |
Juxtaglomerular cell hypertrophy and hyperplasia induced in rhesus monkeys by angiotensin II receptor antagonists.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Dose-Response Relatio | 1994 |
Influence of Losartan, an angiotensin receptor antagonist, on neointimal proliferation in cultured human saphenous vein.
Topics: Angiotensin Receptor Antagonists; Biphenyl Compounds; Cell Division; Graft Occlusion, Vascular; Huma | 1994 |
Tranilast suppresses intimal hyperplasia in the balloon injury model and cuff treatment model in rabbits.
Topics: Angioplasty, Balloon, Coronary; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; | 1996 |
Nifedipine, losartan and captopril effects on hyperplasia of vascular smooth muscle from Ren-2 transgenic rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Genetically Modified; Antihypertensive A | 1997 |
Focal expression of angiotensin II type 1 receptor and smooth muscle cell proliferation in the neointima of experimental vein grafts: relation to eddy blood flow.
Topics: Animals; Antihypertensive Agents; Antimetabolites; Blood Flow Velocity; Bromodeoxyuridine; Cell Divi | 1999 |
Angiotensin II stimulates proliferation of adventitial fibroblasts cultured from rat aortic explants.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Aorta; Blotting, Northern; Cell Division; | 1999 |
Involvement of calcineurin in angiotensin II-induced cardiomyocyte hypertrophy and cardiac fibroblast hyperplasia of rats.
Topics: Angiotensin II; Animals; Animals, Newborn; Atrial Natriuretic Factor; Calcineurin; Calcineurin Inhib | 1999 |
Losartan-induced apoptosis as a novel mechanism for the prevention of vascular lesion formation after injury.
Topics: Animals; Aorta, Thoracic; Apoptosis; Catheterization; DNA Fragmentation; Endothelium, Vascular; Hype | 2000 |
Blood pressure, cardiac, and renal responses to salt and deoxycorticosterone acetate in mice: role of Renin genes.
Topics: Animals; Blood Pressure; Cardiomegaly; Desoxycorticosterone; Hyperplasia; Kidney; Losartan; Mice; Mi | 2002 |
Role of angiotensin subtype 2 receptor in neointima formation after vascular injury.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 1992 |